serval
serveur académique lausannois

UNIL | Université de Lausanne
Faculté de biologie
et de médecine

The Effect of Cigarette Smoking on Diabetic Peripheral Neuropathy: a Systematic Review and Meta-Analysis

Carole Clair, MD, MSc[1], Marya J Cohen, MD, MPH[2], Florian Eichler, MD[3], Kevin J. Selby, MD[1], Nancy A. Rigotti, MD[4]

[1]Department of Ambulatory Care and Community Medicine, Lausanne University Hospital, Lausanne, Switzerland, [2]Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States, [3]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States [4]Massachusetts General Hospital, Tobacco Research and Treatment Center, Division of General Internal Medicine, Harvard Medical School, Boston, Massachusetts, United States

Authors' emails:
Carole Clair: carole.clair@hospvd.ch
Marya Cohen: mjcohen@partners.orgmicro
Florian Eichler: feichler@partners.org
Kevin J. Selby: kevin.selby@hospvd.ch
Nancy Rigotti: nrigotti@partners.org

Corresponding author

Carole Clair

Policlinique Médicale Universitaire

Rue du Bugnon 44

1011 Lausanne, Switzerland

Phone: +41 79 556 81 46

Fax: +41 21 314 61 01

Email address: Carole.Clair@hospvd.ch

Word count

Abstract: 286 words   Manuscript: 3257 words

References: 71

3 tables, 4 figures, 4 supplementary files

1 **Abstract**

2 **Objective:** Studies suggest that smoking might be a risk factor for the development of

3 microvascular complications such as diabetic peripheral neuropathy (DPN). The objective of

4 this study is to assess the relationship between smoking and DPN in people with type 1 or

5 type 2 diabetes.

6 **Research Design and Methods:** A systematic review of PubMed, EMBASE, and Cochrane

7 Clinical Trials databases was conducted from 1966 to November 2014 for cohort, cross-

8 sectional and case-controlled studies that assessed the relationship between smoking and

9 DPN. Separate meta-analyses for prospective cohort studies and case control or cross-

10 sectional studies were performed using random effects models.

11 **Results:** Thirty-eight studies (10 prospective cohort and 28 cross-sectional) were included.

12 The prospective cohort studies included 5,558 participants without DPN at baseline. During a

13 follow up ranging from 2 to 10 years, 1,550 cases of DPN occurred. The pooled unadjusted

14 odds ratio (OR) of developing DPN associated with smoking was 1.26 (95% CI 0.86-1.85;

15 I^2=74.3%; Evidence grade: moderate strength). Overall prospective studies were of moderate

16 to high quality according to the Newcastle-Ottawa scale. Including only the six studies of

17 moderate quality, we found a higher and significant association, with an adjusted OR of 1.73

18 (95% CI 1.48-2.03, I^2=0%, Evidence grade: moderate strength). The cross sectional studies

19 included 27,594 participants. The pooled OR of DPN associated with smoking was 1.42

20 (95% CI 1.21-1.65; I^2=64.5%; Evidence grade: moderate strength). Overall cross-sectional

21 studies were of low to moderate quality, and after exclusion of studies of low quality (n=4),

22 the OR was 1.29 (95% CI 1.13-1.48; I^2=50.5%). There was no evidence of publication bias.

23 **Conclusions:** Smoking may be associated with an increased risk of DPN in people with

24 diabetes. Future studies are needed to test whether smoking cessation reduces the risk of DPN

25   in adult with diabetes.

26   Diabetic peripheral neuropathy, also known as distal symmetrical polyneuropathy or

27   sensorimotor neuropathy, is part of a wider spectrum of microvascular complications of

28   diabetes; other microvascular complications include ulcer/amputations, erectile dysfunction

29   and autonomic dysfunction. Diabetic peripheral neuropathy is the most common

30   microvascular complication of diabetes, affecting approximately 30% of people with

31   diabetes[1-3]. Symptoms include numbness, tingling or burning sensation in the legs and hands,

32   typically in a "stocking and glove" distribution[1]. Ultimately, muscle weakness, loss of

33   reflexes, and foot deformities can result, leading to end clinical sequelae of ulcers, potential

34   infection, and amputation for some patients with poorly-controlled disease.

35   There is a complex interaction between metabolic and vascular factors in the pathogenesis of

36   diabetic peripheral neuropathy[1,4]. Hyperglycemia has been the primary factor described and

37   leads to nerve-cell damage through several mechanisms, including oxidative stress or polyol

38   accumulation[3]. Reduced nerve perfusion, endoneurial hypoxia and endothelial dysfunction

39   also contribute to neuropathy development[1].

40   Previous studies have investigated potential risk factors for diabetic peripheral neuropathy,

41   including hypertension, microalbuminuria, dyslipidemia, and of particular interest, cigarette

42   smoking[5-7]. There appears to be an increased likelihood of neuropathy in people with diabetes

43   who smoke; however, prior studies investigating this relationship only included a small

44   number of participants[7].

45   In order to better assess the relationship between smoking and diabetic neuropathy, we

46   conducted a systematic review and meta-analysis, analyzing cross-sectional, case control,

47   prospective and retrospective cohort studies.

48

49

50

Research Design and Methods

Search Strategy and Selection Criteria

We searched PubMed (1966 to November 2014), Embase (1980 to November 2014) and

Cochrane Clinical Trials (until November 2014). We also searched the references of the

relevant retrieved articles. Studies that assessed the effect of cigarette smoking on the risk of

peripheral neuropathy among patients with type 1 or type 2 diabetes were included

(population of interest). Only participants with diabetes at baseline were included, as we were

interested primarily in the effect of smoking on diabetic complications. The exposure of

interest was cigarette smoking. In order to be considered for inclusion in the systematic

review, all studies had to include a control or comparison group of participants with diabetes

who did not smoke. The outcome of interest was diabetic peripheral neuropathy.

Cohort studies as well as cross-sectional studies and case control studies were included based

on our search results. For cohort studies, we included studies with at least one year of follow-

up because we assumed that there should be a latency period of at least one year for smoking

to impact the development of diabetic neuropathy. We considered studies published in all

languages and did not restrict our search to published studies only.

For our search, we combined 3 search themes: 1) diabetes, 2) smoking and 3) neuropathy.

The full electronic search is available in the **online appendix 1**.

Study Selection

A first screen of retrieved citations was performed based on titles and abstracts; each citation

was screened by 2 different co-authors (CC, MJC, FE or KJS). The inclusion criteria for this

first screen were the following: population with diabetes (type 1 or type 2) at baseline,

neuropathy as one recorded outcome (not necessarily the primary outcome), and

identification as prospective, cohort or cross-sectional studies. We included studies even if

they did not mention smoking exposure in the title or abstract (although it was preferable).

76   Exclusion criteria included gestational diabetes, animal studies, or non-original study design

77   (such as reviews, editorials, and case reports/case series). A second screen was then

78   performed based on full-text review of retained citations. Exclusion criteria were the same as

79   for the first screen, with the addition of the following criteria: 1) Smoking-neuropathy

80   relationship was not assessed and/or data did not allow calculating it by hand; 2) Peripheral

81   neuropathy was not one of the outcomes; or 3) People without diabetes were included.

82   Two reviewers (CC, MJC, FE or KJS) independently reviewed the articles and any

83   disagreement was resolved by consensus.

Data Extraction and Quality Assessment

85   Two authors independently extracted the data from selected studies. To evaluate the risk of

86   bias in individual studies, and assess overall quality, we considered several criteria based on

87   the Newcastle-Ottawa scale[8]. The Newcastle-Ottawa scale for cohort studies has 3 categories:

88   1) selection (representativeness of the exposed cohort, selection of the non-exposed cohort,

89   ascertainment of exposure and demonstration that outcome of interest was not present at start

90   of study) (0-4 points), 2) comparability (comparability of cohorts on the basis of design or

91   analyses) (0-2 points) and 3) outcome (assessment of outcome, was follow-up long enough

92   for outcomes to occur, adequacy of follow-up of cohorts) (0-3 points). The Newcastle-Ottawa

93   scale exists for case control studies and we used a modified version to evaluate the quality of

94   cross-sectional studies. In the modified version we deleted the question on selection of

95   controls (in the "selection" category, yielding to a maximum of 3 points) and the questions on

96   methods of ascertainment for cases and controls and non-response rate (in the "exposure"

97   section, yielding to a maximum of 2 points). We reported the score for each subcategory in

98   the extraction form. We defined Additionally, we evaluated the strength of evidence of the

99   studies using the Cochrane GRADE criteria[9]. By definition, observational studies are

100   considered "Low quality" with the GRADE approach. We upgraded studies to "Moderate

101 quality" if they met at least one of the following factors: 1. "Large magnitude of effect"; 2.

102 "All plausible confounding would reduce a demonstrated effect or suggest a spurious effect

103 when results show no effect"; or 3. "Dose-response gradient". Studies were downgraded to

104 "Very low quality" if at least one of the following factors was present: 1. "Limitations in the

105 design and implementation of available studies suggesting high likelihood of bias"; 2.

106 "Indirectness of evidence"; 3. "Unexplained heterogeneity or inconsistency of results"; 4.

107 "Imprecision of results"; or 5. "High probability of publication bias".

108 Studies reported risk ratios (RR), odds ratios (OR) or absolute numbers when describing the

109 relationship between smoking and diabetic peripheral neuropathy. As most prospective and

110 cross-sectional studies reported ORs and not all studies provided information to convert OR

111 into RR, we used OR in our meta-analyses. For studies that did not provide OR or RR, we

112 calculated unadjusted ORs and Confidence intervals (CI) manually.

113 **Data Synthesis and Analysis**

114 We pooled our results using the DerSimonian and Laird random effect model[10] because we

115 expected to have heterogeneity between studies. Anticipated sources of heterogeneity

116 included study population (people with type 1 versus type 2 diabetes), definition of smoking

117 and definition of neuropathy and were defined *a priori*. We explored other sources of

118 heterogeneity for 3 variables that were added post-hoc: level of adjustment, mean duration of

119 follow-up (for prospective study only) and level of quality assessed with the Newcastle-

120 Ottawa scale[8]. We then performed stratified analyses to assess/explore potential sources of

121 heterogeneity linked to a priori and post hoc variables. In parallel we performed univariate

122 metaregression analyses to quantify potential source of heterogeneity.

123 We performed separate meta-analyses stratified by type of design. To assess heterogeneity,

124 the Q statistic and I squared statistic were calculated[11,12].

125   The possibility of publication bias was assessed using the Begg test and visual inspection of

126   the funnel plot[13,14]. STATA 13 (StataCorp, College Station, Texas) was used for statistical

127   analyses.

128 **Results**

129 **Study Selection**

130 In terms of study selection, the initial search included 2006 citations from PubMed, Embase

131 and Cochrane Clinical Trials databases. After excluding duplicates, 1554 unique citations

132 were available (see **Figure 1**). After the first screen, 126 citations were considered for further

133 review. After a second screen, 88 studies were excluded based on full text review. Agreement

134 between reviewers at this stage was good with a Kappa of 0.78. Reasons for exclusion at this

135 point included no estimate (or numbers to allow manual calculation) of the smoking-

136 neuropathy relationship (n=54), outcome other than peripheral neuropathy (n = 30), or

137 inclusion of participants without diabetes (n = 4). Finally, 38 studies were selected for final

138 inclusion in the systematic review and we performed separate meta-analyses for the 10

139 prospective studies[5,15-23] and the 28 cross-sectional studies[6,7,24-49].

140 **Smoking and incidence of diabetic peripheral neuropathy in prospective cohort studies**

141 The main individual characteristics of the prospective studies are shown in **Table 1**. They

142 include 5,558 participants in total; 3 studies include participants with type 2 diabetes, 6

143 studies included participants with type 1 diabetes and 1 study included both participants with

144 type 1 and type 2 diabetes. Participants were from different settings including inpatient,

145 outpatient and the community; mean age of participants ranged from 25 to 66 years old and

146 mean diabetes duration ranged from 0 to 17 years. All studies excluded participants with

147 neuropathy at baseline and participants were followed for 2 to 10 years. Peripheral

148 neuropathy screening was done by neurological history and examination in most studies[5,17-

149 20,23], by electromyography to measure nerve conduction velocities in one study[15], through

150 measure of vibration perception with biothesiometers in one study[22], and by monofilament

151 examinations in two studies[16,21]. The definition of smoking exposure varied between studies;

152 six studies compared ever smokers (i.e. current and former smokers) to never smokers, one

153   study compared current to non smokers (i.e. former and never smokers) and 3 studies did not

154   clearly specify the smoking comparison groups. Most studies provided OR, two RR and one

155   gave numbers of smokers and non smokers and of participants who developed peripheral

156   neuropathy in each category. All studies except one performed multivariable-adjusted

157   analyses; five controlled for at least A1C and diabetes duration and 4 adjusted for either A1C

158   or diabetes duration and several other confounders - see **Online appendix 2**. The quality of

159   studies varied. Most were considered good quality with maximum points for selection and

160   exposure criteria on the Newcastle-Ottawa scale; however, two were classified as suboptimal

161   for quality with lower scores [15,16]. Using the GRADE criteria, two studies were rated as

162   "Low quality"[21,23], two were downgraded as "Very low"[15,16] because of a poorly defined

163   outcome and risk of selection bias, and six were upgraded to "Moderate quality"[5,17-20,22]

164   mainly due to adjustment for confounding factors and a dose-response gradient. In terms of

165   the incidence of diabetic peripheral neuropathy, 7 studies showed a positive association with

166   smoking and 3 showed a negative association, OR ranged from 0.22 to 10.16. When we

167   pooled the data using a random effects model, the pooled OR was 1.26 (95% CI of 0.86 –

168   1.85) - see **Figure 2**. There was evidence of high heterogeneity across studies as suggested by

169   the *I-squared* statistic ($I^2 = 74.3\%$). Visual inspection of the funnel plot (**Online appendix 3**)

170   and the Begg test (p-value = 0.72) did not suggest publication bias (i.e. no evidence of small

171   negative unpublished studies) but showed a cluster of medium to large negative studies.

172   Trying to correct for eventual small unpublished negative studies using the "trim and fill"

173   method in STATA[50] did not significantly change the results (OR 1.26, 95% CI 0.86-1.83).

174   However, when restricting the analysis to studies of highest quality (i.e with "Moderate

175   quality" using the GRADE criteria for prospective studies) the pooled OR was 1.73 (95% CI

176   1.48-2.03) with no evidence of heterogeneity ($I^2 = 0\%$) (**Figure 3**). In stratified analyses,

177   studies with higher quality, better level of adjustment and longer follow-up showed a stronger

178   positive association between smoking and diabetic peripheral neuropathy (**Table 2**). Studies

179   including people with type 1 diabetes showed increased risks of diabetic peripheral

180   neuropathy for smokers compared with non-smokers whereas studies with people with type 2

181   diabetes did not show a statistically significant association between diabetic peripheral

182   neuropathy and smoking.

183

184   **Smoking and prevalence of diabetic peripheral neuropathy in cross sectional studies**

185   The main individual characteristics of the cross-sectional studies are shown in **Table 3**. They

186   include 27,594 participants in total; 21 studies include people with type 2 diabetes, 3 with

187   type 1 diabetes and 4 with both type 1 and type 2 diabetes. Mean age of participants ranged

188   from 19 to 68 years old and mean diabetes duration ranged from 0 to 20 years. There was a

189   high heterogeneity in the definition of exposure: 7 studies compared current smokers to non

190   smokers (i.e. former and never smokers), 4 studies compared ever smokers (i.e. current and

191   former smokers) to never smokers, 6 studies compared current vs. never smokers, 2 studies

192   compared smokers of 30 or more pack-years to smokers of less than 30 pack-years, one study

193   compared smokers of < 20 pack years to never smokers and 8 studies did not specify the

194   comparison groups. The majority of studies expressed the estimate in OR, two used RR and 9

195   used number or proportions, allowing us to calculate unadjusted OR and 95% CI manually.

196   Seven studies controlled for at least A1C and diabetes duration, one adjusted for either A1C

197   or diabetes duration, 4 adjusted for some confounders but not A1C and diabetes duration and

198   16 did not adjust for potential confounders.- see **Online appendix 4**. Using the GRADE

199   criteria, most studies were rated as "Low quality" and 4 studies were downgraded as "Very

200   low"[25,28-30] mainly because of selection bias, lack of adjustment for confounders and poorly

201   defined exposure and/or outcome. The majority of studies showed increased odds of

202   neuropathy for smokers compared with non-smokers and ORs ranged from 0.68 to 8.20. The

11

203   pooled OR using a random effects model was 1.42 (95% CI of 1.21 – 1.65) - see **Figure 4**.

204   There was evidence of some heterogeneity between studies ($I^2 = 64.5\%$). There was no

205   evidence of publication bias as suggested by both visual inspection of the funnel plots

206   (**Online appendix 5**) and the Begg test (p-value = 0.17). In stratified analyses, studies with

207   higher level of adjustment, studies which included participants with type 1diabetes and those

208   comparing ever vs. never smokers showed a higher and stronger association between

209   smoking and diabetic peripheral neuropathy. (**Table 2**) When analyses were restricted to

210   studies with the highest available level of evidence (i.e. "Low quality" using the GRADE

211   criteria) the pooled OR was 1.29 (95% CI 1.13-1.48; I^2=50.5%). When analyzing only studies

212   which provided adjusted estimates OR was 1.59 (95% CI 1.28-1.97, I^2=43.4%).

213

214

215   **Conclusions**

216   In summary, we found a positive association between smoking and diabetic peripheral

217   neuropathy prevalence and incidence. Although we performed two different meta-analyses,

218   both had similar findings and suggest that smoking is associated with an increased risk of

219   peripheral neuropathy among people with diabetes. There was substantial heterogeneity for

220   both prospective and cross-sectional meta-analyses. However, in stratified analyses, studies

221   with higher level of adjustment, longer follow-up (prospective studies only) and good level of

222   quality showed a stronger positive association between smoking and diabetic peripheral

223   neuropathy with less heterogeneity. Prospective studies comparing ever smokers (current and

224   former smokers) vs. never smokers as well as those including participants with type 1

225   diabetes showed a stronger positive association between smoking and diabetic peripheral

226   neuropathy. However these studies were of higher quality and might not necessarily reflect a

227   real effect modification.

228

229   In people without diabetes, cigarette smoking has been shown to be positively associated

230   with A1C, a surrogate for metabolic control which reflects average glycemia over the past

231   months[51]. A previous meta-analysis has shown that smokers have a 44% increased risk of

232   developing type 2 diabetes compared with non smokers[52]. Among people with diabetes prior

233   studies suggest that smoking is also associated with insulin resistance[53], higher insulin

234   needs[54,55] and thus poor metabolic control[56-61]. As microvascular complications in people

235   with type 1 or type 2 diabetes are highly linked to metabolic control[62,63], A1C probably acts

236   as a mediator in the relationship between smoking and diabetic peripheral neuropathy.

237   However, the fact that the association remains positive after adjustment for A1C suggests that

238   hyperglycemia may not entirely mediate this relationship. Furthermore, smoking is associated

239   with oxidative stress, systemic inflammation and endothelial dysfunction independent of

240   diabetes[64-66]. It might increase the risk of nerve damage through these pathways in parallel to

241   metabolic factors. Smoking may also have direct toxic effects and induce diabetic peripheral

242   neuropathy via hypoxemia and microvascular insufficiency. Similar to what occurs with

243   larger vessels (coronary arteries), smaller arteries, including vasa nervorum, might be

244   damaged by smoking which, in turn, leads to development and progression of diabetic

245   peripheral neuropathy. Smoking has been found to be a causal variable in other microvascular

246   complications such as retinopathy or nephropathy, and similar mechanisms might occur for

247   diabetic peripheral neuropathy to damage those target organs[67]. Finally, confounding factors

248   might also contribute to the association between smoking and diabetic peripheral neuropathy.

249   Smokers might have poorer adherence to recommended self-care compared with non-

250   smokers[68]. Smokers also tend to accumulate unhealthy behaviors such as alcohol abuse, lack

251   of physical activity or a diet rich in fat and poor in fruits and vegetables[69]. Though these

252 factors might contribute to diabetes complications through poorer diabetes control, they do

253 not entirely explain the association, which remains after adjustment for diabetes control.

254

255 Our study has several strengths. We retrieved and pooled a substantial number of studies,

256 assessing the association between smoking and diabetic peripheral neuropathy. Contrary to

257 other microvascular complications such as nephropathy or retinopathy, few studies had to

258 date shown a clear positive association between smoking and diabetic peripheral neuropathy.

259 Indeed, few studies have been directly designed to measure the impact of smoking on

260 diabetic peripheral neuropathy and the complex, multifactorial pathogenesis of diabetic

261 peripheral neuropathy makes it difficult to measure the effect of smoking on a unique

262 outcome. Many prospective studies and some cross-sectional studies, included in our meta-

263 analysis, provided adjusted estimates which permitted control for some potential confounders

264 and exploration of mediating factors.

265

266 Our study has several limitations including the relatively small number of prospective studies

267 and the heterogeneity between studies. Stratified analyses allowed us to address the source of

268 heterogeneity but due to limited number of prospective studies, some conclusions cannot be

269 drawn. For example, studies including participants with type 1 diabetes were of higher

270 quality, and it is thus difficult to conclude that the association between smoking and diabetic

271 peripheral neuropathy is significant only among people with type 1 diabetes and not in those

272 with type 2 diabetes. Another limitation is that the cross-sectional studies were of medium to

273 poor quality. Some did not adjust for the main confounders, some did not assess the outcome

274 clinically, and the smoking exposure was very variable between studies. Finally, we cannot

275 prove that the association we observed is causal because of the design and limitations of our

276 selected studies.

277

Few studies have prospectively assessed the impact of smoking cessation on diabetes control

and complications. We identified only one study which prospectively assessed the impact of

smoking cessation on diabetic peripheral neuropathy [70]. Among 193 participants newly

diagnosed with type 2 diabetes and microalbuminuria, 62% had quit smoking at 12 months.

In this population, the prevalence of diabetic peripheral neuropathy decreased significantly

more in participants who quit smoking compared to those who continued ($p < 0.04$), but no

absolute numbers were given. This was also the case for microalbuninuria, peripheral

vascular disease, blood pressure and dyslipidemia. This unique study of suboptimal quality

suggests that the effect of smoking on diabetic peripheral neuropathy might be reversible, but

more research is needed to assess the effect of smoking cessation on diabetes control and

micro-vascular complications.

In conclusion, smoking might be associated with an increased risk of developing diabetic

peripheral neuropathy. This is an important finding as this exposure is a modifiable behavior

to be targeted in clinical practice, as recommended in diabetes guidelines[71]. Even though we

cannot exclude the possibility of confounding, it seems reasonable based on the consistency

of results and plausibility of biological hypothesis that the association might be causal or at

least of concern for clinicians. Future research should be focused on evaluating the impact of

smoking cessation on improvement of diabetic neuropathy, helping to establish a causal link

between exposure and outcome.

Author's contributions:

CC contributed to the study conception and design, the data research, extraction, led the analyses, and drafted the manuscript, MJC and FE contributed to the study conception and design, the data research, extraction, the interpretation of data and the drafting of the manuscript as well as its review, KJS contributed to the data research, extraction, the interpretation of data and reviewed and edited the manuscript. NAR contributed to the study conception, interpretation of data and critically reviewed the manuscript. All authors read and approved the final manuscript.

Conflict of interest:

NR has been an unpaid consultant to Pfizer and Alere Wellbeing and receives royalties from UpToDate for chapters on smoking cessation. All other authors declare that they do not have a conflict of interest

References

1. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973-88.
2. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377-84.
3. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000;43:957-73.
4. Vincent AM, Calabek B, Roberts L, Feldman EL. Biology of diabetic neuropathy. Handbook of clinical neurology 2013;115:591-606.
5. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-50.
6. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989;38:1456-61.
7. Mitchell BD, Hawthorne VM, Vinik AI. Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990;13:434-7.
8. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. (Accessed February 16, 2015, at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.)
9. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
15. Lehtinen JM, Niskanen L, Hyvonen K, Siitonen O, Uusitupa M. Nerve function and its determinants in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus and in control subjects--a 5-year follow-up. Diabetologia 1993;36:68-72.
16. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997;20:1162-7.
17. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997;46:665-70.
18. Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997;20:322-9.
19. Christen WG, Manson JE, Bubes V, Glynn RJ. Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group. Am J Epidemiol 1999;150:1142-51.
20. Sibal L, Law HN, Gebbie J, Home P. Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. Ann N Y Acad Sci 2006;1084:304-18.
21. Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:517-21.
22. Elliott J, Tesfaye S, Chaturvedi N, et al. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009;32:1896-900.

23.   Uruska A, Araszkiewicz A, Uruski P, Zozulinska-Ziolkiewicz D. Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy. Microvasc Res 2014;92:79-84.

24.   Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1994;17:1172-7.

25.   Gregory R, Tattersall RB, Allison SP. Peripheral neuropathy as a presenting feature of type 2 diabetes: a case-controlled study. Diabet Med 1994;11:407-9.

26.   Matsumoto T, Ohashi Y, Yamada N, Kikuchi M. Hyperglycemia as a major determinant of distal polyneuropathy independent of age and diabetes duration in patients with recently diagnosed diabetes. Diabetes Res Clin Pract 1994;26:109-13.

27.   Zafra Mezcua JA, Mendez Segovia JC, Novalbos Ruiz JP, Costa Alonso MJ, Failde Martinez I. [Chronic complications in patients with type 2 diabetes mellitus cared for at a health center]. Aten Primaria 2000;25:529-35.

28.   Barbosa AP, Medina JL, Ramos EP, Barros HP. Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabetes Metab 2001;27:496-502.

29.   Gomez-Viera N, Soto-Lavastida A, Rosello-Silva H, Gomez de Molina-Iglesias M. [Risk factors involved in symmetrical distal diabetic neuropathy]. Rev Neurol 2001;32:806-12.

30.   Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 2003;20:105-13.

31.   Boru UT, Alp R, Sargin H, et al. Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey. Endocr J 2004;51:563-7.

32.   Tamer A, Yildiz S, Yildiz N, et al. The prevalence of neuropathy and relationship with risk factors in diabetic patients: a single-center experience. Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2006;15:190-4.

33.   Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Annals of Saudi medicine 2007;27:25-31.

34.   Cho HC. The Association between Serum GGT Concentration and Diabetic Peripheral Polyneuropathy in Type 2 Diabetic Patients. Korean diabetes journal 2010;34:111-8.

35.   Jianbo L, Yuche C, Ming S, et al. Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract 2011;93:38-42.

36.   Spallone V, Morganti R, D'Amato C, et al. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. European Journal of Pain 2011;15:153-60.

37.   Wang W, Balamurugan A, Biddle J, Rollins KM. Diabetic neuropathy status and the concerns in underserved rural communities: challenges and opportunities for diabetes educators. Diabetes Educ 2011;37:536-48.

38.   Abougalambou SS, Abougalambou AS. Explorative study on diabetes neuropathy among type II diabetic patients in Universiti Sains Malaysia Hospital. Diabetes & metabolic syndrome 2012;6:167-72.

39.   Ji N, Zhang N, Ren ZJ, et al. Risk factors and pain status due to diabetic neuropathy in chronic long-term diabetic patients in a Chinese urban population. Chin Med J (Engl) 2012;125:4190-6.

40.   Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetology & metabolic syndrome 2012;4:21.

41.   Rasul S, Ilhan A, Wagner L, Luger A, Kautzky-Willer A. Diabetic polyneuropathy relates to bone metabolism and markers of bone turnover in elderly patients with type 2 diabetes: greater effects in male patients. Gender medicine 2012;9:187-96.

42.   Eleftheriadou I, Grigoropoulou P, Mourouzis I, et al. Serum osteoprotegerin levels are associated with peripheral neuropathy in patients with type 2 diabetes. Diabetologia 2013;56:S496.

43.   Molina M, Gonzalez R, Folgado J, et al. [Correlation between plasma concentrations of homocysteine and diabetic polyneuropathy evaluated with the Semmes-Weinstein monofilament test in patients with type 2 diabetes mellitus]. Med Clin (Barc) 2013;141:382-6.

44.   Aubert CE, Michel PL, Gillery P, et al. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes. Diabetes Metab Res Rev 2014;30:679-85.

45.   Bener A, Al-Laftah F, Al-Hamaq AO, Daghash M, Abdullatef WK. A study of diabetes complications in an endogamous population: an emerging public health burden. Diabetes & metabolic syndrome 2014;8:108-14.

46.   Brownrigg JR, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart 2014;100:1837-43.

47.   Hu Y, Liu F, Shen J, et al. Association between serum cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population. Eur J Endocrinol 2014;171:641-8.

48.   Jaiswal M, Divers J, Isom S, et al. Prevalence and clinical correlates of diabetic peripheral neuropathy among youth with type 1 diabetes: Search for diabetes in youth cohort study. Diabetes 2014;63:A148-A9.

49.   Wang DD, Bakhotmah BA, Hu FB, Ali Alzahrani H. Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: A cross-sectional study. PloS one 2014;9.

50.   Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.

51.   Clair C, Bitton A, Meigs JB, Rigotti NA. Relationships of cotinine and self-reported cigarette smoking with hemoglobin A1c in the U.S.: results from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011;34:2250-5.

52.   Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298:2654-64.

53.   Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:3619-24.

54.   Madsbad S, McNair P, Christensen MS, et al. Influence of smoking on insulin requirement and metbolic status in diabetes mellitus. Diabetes Care 1980;3:41-3.

55.   Bott U, Jorgens V, Grusser M, Bender R, Muhlhauser I, Berger M. Predictors of glycaemic control in type 1 diabetic patients after participation in an intensified treatment and teaching programme. Diabet Med 1994;11:362-71.

56.   Melin EO, Thunander M, Svensson R, Landin-Olsson M, Thulesius HO. Depression, obesity, and smoking were independently associated with inadequate glycemic control in patients with type 1 diabetes. Eur J Endocrinol 2013;168:861-9.

57.   Gunton JE, Davies L, Wilmshurst E, Fulcher G, McElduff A. Cigarette smoking affects glycemic control in diabetes. Diabetes Care 2002;25:796-7.

58.   Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol 2005;152:491-9.

59.   Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes--data from the National Diabetes Register in Sweden. Diabetes Metab 2004;30:261-8.

60.   Sargeant LA, Khaw KT, Bingham S, et al. Cigarette smoking and glycaemia: the EPIC-Norfolk Study. European Prospective Investigation into Cancer. Int J Epidemiol 2001;30:547-54.

61.   Lundman BM, Asplund K, Norberg A. Smoking and metabolic control in patients with insulin-dependent diabetes mellitus. J Intern Med 1990;227:101-6.

62.   Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014;2:CD009122.

63.   Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013;11:CD008143.

64.   Winkelmann BR, Boehm BO, Nauck M, et al. Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in non-diabetic individuals with coronary artery disease. Curr Med Res Opin 2001;17:132-41.

65.   Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 2003;46:79-90.

66.   Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46:91-111.

67.   Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003;45:405-13.

68.   Yu MK, Lyles CR, Bent-Shaw LA, Young BA. Sex disparities in diabetes process of care measures and self-care in high-risk patients. Journal of diabetes research 2013;2013:575814.

69.   Chiolero A, Wietlisbach V, Ruffieux C, Paccaud F, Cornuz J. Clustering of risk behaviors with cigarette consumption: A population-based survey. Prev Med 2006;42:348-53.

70.   Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011;60:1456-64.

71.   Standards of medical care in diabetes--2014. Diabetes Care 2014;37 Suppl 1:S14-80.

Tables and figures legends:

Table 1: Characteristics of prospective studies included in the Meta-analysis

Table 2: Stratified analyses for prospective studies and cross-sectional studies

Table 3: Characteristics of cross-sectional studies included in the Meta-analysis

Figure 1: Study flow diagram

Figure 2: Forest plot for prospective studies: Adjusted Odds ratios of Neuropathy for Smokers Compared with Nonsmokers

Figure 3: Forest plot for prospective studies of highest quality ("moderate quality" using the GRADE criteria): Adjusted Odds ratios of Neuropathy for Smokers Compared with Nonsmokers

Figure 4: Forest plot for cross-sectional studies: Adjusted Odds Ratios of Neuropathy for Smokers Compared with Nonsmokers

Online appendix files

Online appendix 1: Electronic search strategy

Online appendix 1: Level of adjustment and quality of prospective studies

Online appendix 2: Funnel plot for prospective studies

Online appendix 3: Level of adjustment and quality of cross-sectional studies

Online appendix 4: Funnel plot for cross-sectional studies

Table 1: Characteristics of prospective studies included in the Meta-analysis

Author, year	Country/ region	Sample size	Population	Type of DM	% men	Mean age	Mean DM duration	Neuropathy screening	Smoking comparison	FUP y	Estimate
Lehtinen et al., 1993	Finland	113	Subjects with newly diagnosed DM from the community	2	51	56.4	0	Nerve conduction velocities	NS	5	N
Adler et al., 1997	USA	387	US veterans followed in an outpatient clinic	Both	96	61.7	9.8	Monofilament examination	Current vs. former + never smokers	2.6	OR
Forrest et al., 1997	USA	453	Subjects with childhood-onset DM	1	49	25.1	16.9	Neurological examination	Current + former vs. never smokers	5.3	RR
Sands et al., 1997	USA	231	Biethnic population in Colorado	2	NS	NS	NS	Neurological examination and history	Current + former vs. never smokers	4.7	OR
Christen et al., 1999	USA	407	Participants of a drug (Sorbinil) multi-center trial	1	75	31.4	6.5	Neurological examination and history	Current + former vs. never smokers*	2	RR
Tesfaye et al., 2005	Europe	1172	Subjects randomly selected from 31 diabetes clinics	1	51	30.7	12.4	Neurological examination	Current + former vs. never smokers	7.3	OR
Sibal et al., 2006	UK	334	Outpatients who attended diabetes services	1	54	39	20	Neurological examination and history	NS	9	OR
Gerrits et al.,	Netherlands	973	Subjects from	2	46	66	4	Monofilament	NS	3.1	OR

2008			primary care					examination			
Elliott et al., 2009	Europe	1407	Subjects randomly selected from 31 diabetes clinics	1	48	31.5	13.1	Vibration perception threshold measured by biothesiometers	Current + former vs. never smokers	7.3	OR
Uruska et al., 2014	Poland	81	Patients treated with intensive Insulin from onset of disease	1	63	34	10	Neurological examination (monofilament, vibration, temperature and ankle reflex)	Current + former vs. never smokers	10	OR

DM = diabetes mellitus, NS = non specified, FUP = follow-up, OR=Odds ratio, RR=Relative risk, N=number or proportion

* In the age-adjusted analyses, compared current smokers to never smokers, in the multivariable-adjusted model compares ever to never smokers

Table 2: Stratified analyses for prospective and cross-sectional studies

Stratified analysis	Total number of trials	OR	(95% CI)	*I-squared*	P value from metareg[+]
Adjustment for confounding factors					
Prospective studies					0.71
Adjusted for at least HbA1c and DM duration	5	1.47	(1.01-2.13)	71.8%	
Not adjusted for HbA1c and DM duration	5	1.03	(0.34-3.09)	79.2%	
Cross sectional studies					0.31
Adjusted for at least HbA1c and DM duration	7	1.59	(1.23-2.06)	43.6%	
Not adjusted for HbA1c and DM duration	21	1.36	(1.11-1.66)	69.2%	
Type of diabetes					
Prospective studies					0.02
Type 1	6	1.74	(1.48-2.04)	0%	
Type 2	3	0.65	(0.16-2.71)	83.2%	
Both	1	0.22	(0.07-0.66)	--	
Cross sectional studies					0.19
Type 1	3	3.02	(2.03-4.47)	11.7%	
Type 2	21	1.24	(1.08-1.44)	50.5%	
Both	4	1.55	(0.94-2.57)	63.2%	
Smoking exposure					
Prospective studies					0.007
Ever (current + former) vs. never smoker	6	1.77	(1.51-2.08)	0%	
Current vs. never smoker	1	0.22	(0.07-0.66)	--	
Non specified	3	0.47	(0.21-1.06)	31.6%	
Cross sectional studies					0.79
Ever (current + former) vs. never smoker	4	1.78	(1.39-2.29)	10.6%	
Current vs. non smokers (former + never)	7	1.38	(0.87-2.20)	70.0%	

Current vs. never smoker	6	1.58	(1.00-2.48)	74.2%	
Non specified or other definition	11	1.28	(1.03-1.60)	57.2%	
Mean follow-up					
Prospective studies					0.322
< 5 years	4	0.77	(0.25-2.31)	86.4%	
≥ 5 years	6	1.63	(1.21-2.21)	47.7%	
Level of quality (GRADE criteria)					
Prospective studies					0.007
Moderate	6	1.73	(1.48-2.03)	0%	
Low	2	1.57	(0.05-50.83)	91%	
Very low	2	0.27	(0.11-0.65)	0%	
Cross sectional studies					0.75
Low	22	1.29	(1.13-1.48)	50.5%	
Very low	4	1.30	(0.61-2.75)	68.3%	

+ P-value for metaregression using the "metareg" Stata command

Table 3: Characteristics of cross-sectional studies included in the Meta-analysis

Author	Country	Sample size	Population	Type of DM	% men	Mean age	Mean DM duration	Neuropathy screening	Smoking measure	Estimate
Maser et al., 1989[66666666666666666666]	USA	363	Cohort of patients with recent diagnosis	1	50	28.4	19.9	Neurological examination and history	Current + former vs. never smokers	OR
Mitchell et al., 1990	USA	214	Patients admitted to the inpatient diabetic clinic of a University hospital	1	37	46	14.7	Neurological examination and history	Smoking ≥ 30 vs. < 30 pack-years	OR
Franklin et al., 1994	USA	277	Biethnic population in Colorado	2	43	59.5	9.7	Neurological examination and history	< 20 pack-years vs. never smokers	OR
Gregory et al., 1994	UK	136	Newly diagnosed patients attending a hospital	2	50	68	0	Neurological examination and history	Smoking ≥ 30 vs. < 30 pack-years	N
Matsumoto et al., 1994	Japan	742	Outpatients who visited the diabetic unit of a department of internal medicine	2	54	49	1.3	Information from patient's charts and neurological examination t	NS	OR
Zafra Mezcua et al., 2000	Spain	504	Patients attending a medical outpatient clinic	2	42	63.9	8.6	Medical chart review	NS	RR
Barbosa et al., 2001	Portugal	93	Patients from primary health cares	2	40	65.4	10.1	Neurological examination	Current vs. never smokers	N
Gomez-Viera et al.,	Cuba	200	Patients diagnosed in clinic	Both	37.6	.	.	Clinical diagnosis with	NS	RR

2001								neuroinduction exam corroboration		
Tapp et al., 2003	Australia	821	Population-based survey	2	51	63.1	0.2	Neurological examination and history	Current vs. former + never smokers	OR
Boru et al., 2004	Turkey	866	Patients who attended a diabetic clinic	2	40	57.2	8.5	Neurological examination and history	NS	OR
Tamer et al., 2006	Turkey	191	Patients with type 2 DM recruited	2	43	58.7	.	Neurological examination and electromyography	Current + former vs. never smokers	OR
Al-Mahroos et al., 2007	Bahrain	1477	Patients from specialized clinics	2	43	57.3	9.5	Neurological examination and history	NS	OR
Cho et al., 2010	Korea	90	Patients who underwent work-ups for peripheral polyneuropathy	2	51	59	8.7	Neurological examination and history	NS	OR
Jianbo et al., 2011	China	227	Inpatients and outpatients	2	.	64.5	9.3	Neurologic exam and electromyography	Current vs. never smoker	N
Spallone et al., 2011	Italy	191	Diabetic patients with suspected neuropathic pain referred to a center	Both	56.5	58.6	16.7	History + electrodiagnostic studies in selected cases	NS	OR
Wang et al., 2011	USA	816	Patients referred to a diabetes education program	2	45.2	57	.	Questionnaires and review of medical records	Current + former vs. never	OR

									smokers	
Abougalambou et al., 2012	Malaysia	1077	Patient followed in an outpatient diabetic clinic	2	45.2	.	.	Neurologic exam	Current vs. former+ never smokers	OR
Ji et al., 2012	China	565	Mostly inpatients	2	47.8	66.6	16.2	Medical history and/or symptoms and/or neurological exam	Current vs. never smokers	N
Katulanda et al., 2012	Sri Lanka	337	Non institutionalized adults from the community	2	37.1	56.8	6.3	Symptoms and neurologic exam	Current vs. former + never smokers	OR
Rasul et al., 2012	Austria	120	Patients from an outpatient clinic	2	59.2	62.9	12.7	Neurological exam and nerve conduction velocity	Current vs. never smokers	N
Eleftheradiou et al., 2013 (Abstract)	Greece	71	Patients from an outpatient clinic	2	63.4	67.7	15	Neuropathy symptom and neuropathy disability scores, vibration perception threshold	Current vs. former + never smokers	OR
Molina et al., 2013	Spain	405	Patients from a diabetes clinic and primary care clinic	2	58.3	66	12.7	Semmes-Weinstein monofilament test	Current vs. former + never smokers	N
Aubert et al., 2014	France	198		2	79.8	65	13	Neuropathy disability score or inability to perceive	Current vs. former + never smokers	N

	Country	N	Population	Type				Diagnosis method	Comparison	Measure
								monofilament		
Bener et al., 2014	Qatar	1633		Both	51.6	45.3	7.3	Not specified	Current vs. former + never smokers	OR
Brownrigg et al., 2014	UK	13043		2	51.8	63.8	.	Semmes-Weinstein monofilament test	Current vs. never smokers	N
Hu et al., 2014	China	937	Diabetic inpatients ate a clinical medical center of diabetes	2	57.7	59.6	9.8	Neurological examination and nerve conduction tests	NS	N
Jaiswal et al., 2014 (Abstract)	USA	1448	Participants to the SEARCH for diabetes in youth study	1	50	19	8	Symptoms and neurologic exam	Current vs. never smokers	OR
Wang et al., 2014	Saudi Arabia	552	People with diabetes from the community	Both	62.7	53.4	.		Current + former vs. never smokers	OR

DM = diabetes mellitus, NS = non specified, FUP = follow-up, OR=Odds ratio, RR=Relative risk, N=number or proportion

Figure 1:

```
┌─────────────────────────────────────┐
│ 2006  Records identified through     │
│       database searching (PubMed,    │
│       Embase, and Cochrane)          │
└─────────────────────────────────────┘
                  │
                  ▼
┌─────────────────────────────────────┐
│ 1554  Records after duplicates       │
│       removed                        │
└─────────────────────────────────────┘
                  │
                  ▼
┌──────────────────────┐        ┌──────────────────────┐
│ 1554  Records        │───────▶│ 1429 Records excluded │
│       screened       │        │                       │
└──────────────────────┘        └──────────────────────┘
                  │
                  ▼
┌──────────────────────┐        ┌──────────────────────────────┐
│ 126  Full-text       │        │ 88  Excluded based on full-  │
│      articles        │───────▶│     text review              │
│      assessed for    │        │ 54  Smoking neuropathy       │
│      eligibility     │        │     relationship not assessed│
└──────────────────────┘        │ 30  Outcome is not           │
                  │             │     Peripheral neuropathy    │
                  ▼             │ 4   People without           │
┌──────────────────────┐        │     diabetes included        │
│ 38  Studies included │        └──────────────────────────────┘
│     in meta-analysis │
└──────────────────────┘
          │         │
         ╱           ╲
        ▼             ▼
┌──────────────────┐  ┌──────────────────────────┐
│ 10 Prospective   │  │ 28 Cross-sectional       │
│    cohort        │  │    studies               │
└──────────────────┘  └──────────────────────────┘
```

Figure 2

Study ID		Odds Ratio (95% CI)	% Weight
Lehtinen (1993)		0.37 (0.09, 1.44)	5.36
Adler (1997)		0.22 (0.07, 0.66)	7.05
Forrest (1997)		1.73 (1.06, 2.82)	13.69
Sands (1997)		2.20 (0.99, 4.70)	10.22
Christen (1999)		1.87 (1.09, 3.21)	13.06
Tesfaye (2005)		1.55 (1.17, 2.04)	16.10
Sibal (2006)		1.11 (0.32, 3.81)	6.24
Gerrits (2008)		0.29 (0.11, 0.75)	8.40
Elliott (2009)		1.85 (1.27, 2.07)	16.41
Uruska (2014)		10.16 (1.59, 64.95)	3.46
Overall (I-squared = 74.3%, p = 0.000)		1.26 (0.86, 1.85)	100.00

Odds Ratio and 95% CI

Dashed vertical line represents the estimated pooled effect size estimate; points in grey squares with lines represent odds ratios and 95% CIs of individual studies; the open diamond represent a visual summary of the overall 95% CI of the effect estimate of smoking on the incidence of DPN. Studies on the right of the 1 vertical line indicate a positive association between smoking and DPN, studies on the left a negative association.

Figure 3

Study ID		Odds Ratio (95% CI)	% Weight
Forrest (1997)		1.73 (1.06, 2.82)	10.55
Sands (1997)		2.20 (0.99, 4.70)	4.16
Christen (1999)		1.87 (1.09, 3.21)	8.66
Tesfaye (2005)		1.55 (1.17, 2.04)	32.67
Sibal (2006)		1.11 (0.32, 3.81)	1.65
Elliott (2009)		1.85 (1.27, 2.07)	42.31
Overall (I-squared = 0.0%, p = 0.872)		1.73 (1.48, 2.03)	100.00

.1 — 1 — 10

Odds Ratio and 95% CI

Dashed vertical line represents the estimated pooled effect size estimate; points in grey squares with lines represent odds ratios and 95% CIs of individual studies; the open diamond represent a visual summary of the overall 95% CI of the effect estimate of smoking on the incidence of DPN. Studies on the right of the 1 vertical line indicate a positive association between smoking and DPN, studies on the left a negative association.

Figure 4

Study ID		Odds Ratio (95% CI)
Maser (1989)		2.22 (1.29, 3.83)
Mitchell (1990)		3.32 (1.15, 9.58)
Franklin (1994)		1.49 (0.69, 3.22)
Gregory (1994)		1.15 (0.47, 2.81)
Matsumoto (1994)		0.79 (0.55, 1.13)
Zafra Mezcua (2000)		1.13 (0.60, 2.13)
Barbosa (2001)		0.96 (0.16, 5.62)
Gomez-Viera (2001)		2.59 (1.66, 4.03)
Tapp (2003)		0.68 (0.30, 1.53)
Boru (2004)		1.30 (0.89, 1.91)
Tamer (2006)		2.33 (1.22, 4.45)
Al-Mahroos (2007)		1.24 (1.01, 1.31)
Cho (2010)		1.10 (0.30, 4.60)
Jianbo (2011)		0.69 (0.24, 2.02)
Spallone (2011)		1.95 (0.47, 8.09)
Wang (2011)		1.76 (1.28, 2.41)
Abougalambou (2012)		1.00 (0.70, 1.42)
Ji (2012)		1.48 (0.97, 2.24)
Katulanda (2012)		5.90 (1.41, 9.70)
Rasul (2012)		1.82 (0.74, 4.48)
Eleftheradiou (A) (2013)		8.20 (1.41, 47.92)
Molina (2013)		0.86 (0.51, 1.44)
Aubert (2014)		1.76 (0.71, 4.37)
Bener (2014)		1.09 (0.67, 1.77)
Brownrigg (2014)		1.21 (1.05, 1.40)
Hu (2014)		0.98 (0.74, 1.30)
Jaiswal (A) (2014)		4.00 (2.30, 6.90)
Wang (2014)		1.17 (0.66, 2.08)
Overall (I-squared = 64.5%, p = 0.000)		1.42 (1.21, 1.65)

Odds Ratio and 95% CI

Dashed vertical line represents the estimated pooled effect size estimate; points in grey squares with lines represent odds ratios and 95% CIs of individual studies; the open diamond represent a visual summary of the overall 95% CI of the effect estimate of smoking on the prevalence of DPN. Studies on the right of the 1 vertical line indicate a positive association between smoking and DPN, studies on the left a negative association.

Online appendix 1

A) Electronic search strategy for PubMed (performed on November 17, 2014):

((polyneuropath*[tiab] OR neuropath*[tiab]) OR ("Peripheral Nervous System Diseases"[Mesh]) OR ((("Diabetic Neuropathies"[Mesh]) OR "Polyneuropathies"[Mesh]) OR "Diabetic Foot"[Mesh])) AND (("Diabetes Mellitus, Type 2"[Mesh] OR "Diabetes Mellitus, Type 1"[Mesh]) OR (diabetes[tiab] OR diabetic*[tiab])) AND (((("Smoking"[Mesh] OR "Smoking Cessation"[Mesh]) OR ("Tobacco Use Cessation"[Mesh] OR "Tobacco Use Disorder"[Mesh] OR "Tobacco, Smokeless"[Mesh] OR "Tobacco"[Mesh])) OR "Nicotine"[Mesh]) OR (smoking[tiab] OR smoker*[tiab] OR cigarett*[tiab] OR tobacco[tiab] OR nicotine[tiab])).

B) Electronic search strategy for Embase (performed on November 17, 2014):

'diabetic neuropathy'/exp OR 'peripheral neuropathy'/exp OR 'polyneuropathy'/exp AND [embase]/lim

'diabetes mellitus'/exp OR 'non insulin dependent diabetes mellitus'/exp OR 'insulin dependent diabetes mellitus'/exp AND [embase]/lim

'smoking'/exp OR 'smoking cessation'/exp OR 'smokeless tobacco'/exp OR 'tobacco dependence'/exp OR 'tobacco'/exp OR 'nicotine'/exp AND [embase]/lim

**Online appendix 2:** Level of adjustment and quality of prospective studies

Author, year	Adjustment	Quality score (NOS scale)		
		Selection[1]	Comparability[2]	Exposure[3]
Lehtinen et al., 1993	-	***	-	**
Adler et al., 1997	HbA1c, height, history of ulcer, age, alcohol, albumin, creatinin	*	*	*
Forrest et al., 1997	HbA1c, DM duration, height, hypertension	****	**	***
Sands et al., 1997	HbA1c, DM duration, age, insulin treatment, ethnicity, gender, history of myocardial infarct, angina	****	**	***
Christen et al., 1999	HbA1c, age, drug (Sorbinil vs plabebo), height, gender	****	*	***
Tesfaye et al., 2005	HbA1c, DM duration	****	*	***
Sibal et al., 2006	DM duration, systolic blood pressure, diastolic blood pressure, total cholesterol, glomerular filtration rate, triglycerides, microalbuminuria, retinopathy, foot complications	****	*	***
Gerrits et al., 2008	HbA1c, DM duration, sex, systolic blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, body-mass index, skin autofluorescence	****	**	***
Elliott et al., 2009	HbA1C, DM duration, hypertension, body-mass index, retinopathy, cardiovascular disease history, cholesterol, triglycerides, albumin	****	*	***
Uruska et al., 2014	HbA1c, age, sexe, hypertension	***	*	*

HbA1c= glycated heamoglobin, DM=diabetes mellitus

NOS scale = Newcastle Ottawa scale

[1] Selection : minimum = -, maximum =****, [2] Comparability: minimum = -, maximum = **, [3] Exposure: minimum = -, maximum = ***

Online appendix 3

Funnel plot with pseudo 95% confidence limits

Online appendix 4: Level of adjustment and quality of cross-sectional studies

Author, year	Adjustment	Quality score (NOS scale)		
		Selection[1]	Comparability[2]	Exposure[3]
Maser et al., 1989[666666666666666666666]	HbA1c, DM duration, HDL-cholesterol, macrovascular disease	*	**	*
Mitchell et al., 1990	HbA1c, DM duration	*	*	*
Franklin et al., 1994	HbA1c, DM duration, age, ethnicity, systolic blood pressure, height, insulin use, alcohol, serum lipids, peripheral vascular disease, fasting C-peptide	*	**	*
Gregory et al., 1994	-	*	-	*
Matsumoto et al., 1994	-	**	-	**
Zafra Mezcua et al., 2000	-	***	-	*
Barbosa et al., 2001	-	*	-	*
Gomez-Viera et al., 2001	-	*	-	*
Tapp et al., 2003	-	*	-	*
Boru et al., 2004	HbA1c, DM duration, retinopathy, hypertension, hyperlipidemia, alcohol	*	**	*
Tamer et al., 2006	HbA1c, DM duration, gender, age, hypertension, cholesterol, triglycerides, drug usage, neuropathic complaints	*	**	*
Al-Mahroos et al., 2007	HbA1c, DM duration, gender, age, hypertension, cholesterol, triglycerides, body-mass index, waist circumference	*	**	*

Cho et al., 2010	Retinopathy, systolic blood pressure, diastolic blood pressure, gamma-glutamyl transferase, Aspartate amino transferase, urine albunine/creatinie, C-reactive protein	*	*	*
Jianbo et al., 2011	-	***	-	*
Spallone et al., 2011	HbA1c, DM duration, gender, age, systolic blood pressure, triglycerides, peripheral arterial disease, Valsalva ratio, type of DM, body-mass index, waist circumference , Michigan Diabetic Neuropathy Score	*	**	*
Wang et al., 2011	DM duration, sex, race, education, self foot exam, foot exam by medical doctor	*	*	*
Abougalambou et al., 2012	-	***	-	*
Ji et al., 2012	-	***	-	*
Katulanda et al., 2012	-	***	-	*
Rasul et al., 2012	-	***	-	*
Eleftheradiou et al., 2013 (abstract)	Sex, age, body-mass index			
Molina et al., 2013	-	**	-	**
Aubert et al., 2014	-	***	-	**
Bener et al., 2014	-	**	-	*
Brownrigg et al., 2014	-	****	-	**
Jaiswal et al., 2014 (abstract)	-			
Hu et al., 2014	-	**	-	**

Wang et al., 2014	Sex, age, nationality	***	*	*

HbA1c= glycated heamoglobin, DM=diabetes mellitus, NA= not applicable

NOS scale = Newcastle Ottawa scale

[1] Selection : minimum = -, maximum =***, [2] Comparability: minimum = -, maximum = **, [3] Exposure: minimum = -, maximum = **

Online appendix 5

Funnel plot with pseudo 95% confidence limits